Galatea Bio, a Miami-based AI-powered genomic research and clinical testing company, has raised $25 million in funding to expand its clinico-genomics platform. The round included investments from F-Prime, Helios Digital Ventures, Digitalis Ventures, AME Cloud, CEI Ventures, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics.
Founded by CEO and President Carlos D. Bustamante, Ph.D., Galatea Bio integrates clinical genomics, a proprietary biobank, and advanced AI algorithms to accelerate precision medicine. The company focuses on diverse populations, refining genetic risk prediction, biomarker discovery, and clinical trial optimization.
Bustamante said the funding will support multi-modal data integration and AI-driven applications to improve diagnostic accuracy and drive breakthroughs across Mendelian and complex diseases.
Featured image. Credit: Galatea Bio
